X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be focusing on the development of SC291, which is a hypoimmune allogeneic CD19-directed CAR T cell therapy, for relapsed and/or refractory B-cell malignancies, including Non-Hodgkin lymphoma and Chronic lymphocytic leukemia.
Lead Product(s): SC291
Therapeutic Area: Oncology Product Name: SC291
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $189.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 12, 2024
Details:
The net proceeds will be focusing on the development of SC291, which is a hypoimmune allogeneic CD19-directed CAR T cell therapy, for relapsed and/or refractory B-cell malignancies, including Non-Hodgkin lymphoma and Chronic lymphocytic leukemia.
Lead Product(s): SC291
Therapeutic Area: Oncology Product Name: SC291
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $165.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 08, 2024
Details:
The net proceeds will be focusing on the development of SC291, which is a hypoimmune allogeneic CD19-directed CAR T cell therapy, for relapsed and/or refractory B-cell malignancies, including Non-Hodgkin lymphoma and Chronic lymphocytic leukemia.
Lead Product(s): SC291
Therapeutic Area: Oncology Product Name: SC291
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 07, 2024
Details:
SC262 is a hypoimmune, CD22-directed allogeneic CAR T cell therapy derived from healthy donor CD4+ and CD8+ T cells. It is under preclinical development for the treatment of patients with relapsed or refractory B-cell malignancies.
Lead Product(s): SC262
Therapeutic Area: Oncology Product Name: SC262
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
UP421 is an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, which is being evaluated for the treatment of patients with type 1 diabetes.
Lead Product(s): UP421
Therapeutic Area: Endocrinology Product Name: UP421
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Details:
SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis.
Lead Product(s): SC291
Therapeutic Area: Nephrology Product Name: SC291
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
SC291 is a CD19-targeted allogeneic CAR T cell therapy developed using Sana’s hypoimmune platform. SC291 may result in longer CAR T cell persistence and a higher rate of durable complete responses for patients with B-cell lymphomas or leukemias.
Lead Product(s): SC291
Therapeutic Area: Oncology Product Name: SC291
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
The company expects to study SG295, an in vivo CAR T with CD8-targeted fusosome delivery of a CD19-targeted CAR, in B cell malignancies. With increased potency, SG295 has the potential to generate a comparable no. of CAR T cells to current ex vivo manufacturing processes.
Lead Product(s): SG295
Therapeutic Area: Oncology Product Name: SG295
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2022
Details:
The SC291 preclinical data demonstrate these hypoimmunogenic CAR T cells are able to evade both the innate and adaptive arms of the immune system while retaining their antitumor activity.
Lead Product(s): SC291
Therapeutic Area: Oncology Product Name: SC291
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
First demonstration of SC291, survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression.
Lead Product(s): SC291
Therapeutic Area: Oncology Product Name: SC291
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
